{
  "nct_id": "DS1062-A-U303",
  "age": "Adults",
  "cancer_center_accrual_goal_upper": 0,
  "data_table4": "Interventional",
  "drug_list": {
    "drug": [
      {
        "drug_name": "Dao-DXd"
      },
      {
        "drug_name": "Pembrolizumab"
      },
      {
        "drug_name": "Carboplatin"
      },
      {
        "drug_name": "Pemetrexed"
      }
    ]
  },
  "long_title": "A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",
  "management_group_list": {
    "management_group": [
      {
        "is_primary": "Y",
        "management_group_name": "Group 1"
      }
    ]
  },
  "oncology_group_list": {
    "oncology_group": [
      {
        "group_name": "Group 1",
        "is_primary": "N"
      }
    ]
  },
  "phase": "3",
  "principal_investigator": "Dr. Victor LEE",
  "program_area_list": {
    "program_area": [
      {
        "is_primary": "Y",
        "program_area_name": "Program 1"
      }
    ]
  },
  "protocol_id": 2,
  "protocol_no": "2025010800",
  "protocol_target_accrual": 0,
  "protocol_type": "",
  "prior_treatment_requirements": [
    "Stage IIIB or IIIC NSCLC who are not candidates for surgical resection or definitive chemoradiation, or Stage IV NSCLC",
    "PD-L1 TPS < 50%",
    "Negative test results for EGFR, ALK, ROS1, and other actionable driver kinases with locally approved therapies",
    "Have not received prior systemic treatment for advanced or metastatic NSCLC"
  ],
  "short_title": "A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",
  "site_list": {
    "site": []
  },
  "sponsor_list": {
    "sponsor": []
  },
  "staff_list": {
    "protocol_staff": []
  },
  "status": "open to accrual",
  "summary": "",
  "treatment_list": {
    "step": [
      {
        "arm": [
          {
            "arm_code": "Arm A",
            "arm_internal_id": 1111,
            "arm_description": "Treatment with Dao-DXd + Pembrolizumab + Carboplatin",
            "arm_suspended": "N"
          },
          {
            "arm_code": "Arm B",
            "arm_internal_id": 2222,
            "arm_description": "Treatment with Dato-DXd + Pembrolizumab",
            "arm_suspended": "N"
          },
          {
            "arm_code": "Arm C",
            "arm_internal_id": 3333,
            "arm_description": "Treatment with Pembrolizumab + Pemetrexed + Carboplatin",
            "arm_suspended": "N"
          }
        ],
        "step_code": "1",
        "step_type": "Registration",
        "step_internal_id": 1111,
        "match": [
          {
            "and": [
              {
                "clinical": {
                  "oncotree_primary_diagnosis": "Non-Small Cell Lung Cancer",
                  "pdl1_status": "Low"
                }
              },
              {
                "and": [
                  {
                    "genomic": {
                      "hugo_symbol": "!EGFR",
                      "variant_category": "Mutation"
                    }
                  },
                  {
                    "genomic": {
                      "hugo_symbol": "!ALK",
                      "variant_category": "Mutation"
                    }
                  },
                  {
                    "genomic": {
                      "hugo_symbol": "!ROS1",
                      "variant_category": "Mutation"
                    }
                  }
                ]
              }
            ]
          }
        ]
      }
    ]
  }
}